近年来,伴随免疫相关不良反应管理能力的提升以及伴随诊断技术的发展,PD-1药物的临床接受度和使用规范性显著提高的同时,国内 PD-1 市场整体正稳健增长。而值得一提的是,在越加激烈的竞争环境下,君实生物、百济神州等多家企业依然有核心产品在2025年销售额大增。君实生物(特瑞普利单抗 / 拓益)近日,君实生物发布2025年度业绩快报公告,全年营业总收入24.98亿元,较上年增长28.23%;归母...
Source Link近年来,伴随免疫相关不良反应管理能力的提升以及伴随诊断技术的发展,PD-1药物的临床接受度和使用规范性显著提高的同时,国内 PD-1 市场整体正稳健增长。而值得一提的是,在越加激烈的竞争环境下,君实生物、百济神州等多家企业依然有核心产品在2025年销售额大增。君实生物(特瑞普利单抗 / 拓益)近日,君实生物发布2025年度业绩快报公告,全年营业总收入24.98亿元,较上年增长28.23%;归母...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.